Anthem Biosciences share price
NSE: ANTHEMBSE: 544449Pharmaceuticals & BiotechnologyMid Cap
Anthem Biosciences Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 2025 · Issue price ₹570
Last close ₹830.15down ₹2.00 (0.24%)BSE ₹831.00
Share price at the NSE close on 29 Oct 2026. Previous close ₹832.15.
29 Oct: open ₹831.20, high ₹835.10, low ₹819.10
52-week range of traded prices to 29 Oct 2026
₹579.15Low, 2 Feb 2026₹977.55High, 9 Sep 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹46,781 Cr226th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 81.23
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 15.38
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.24%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 18.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.02
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,06,08953.6% delivered
About Anthem Biosciences
Anthem Biosciences is a contract research, development and manufacturing organisation (CRDMO): it discovers, develops and makes drug molecules for pharmaceutical and biotechnology companies around the world, from early research to commercial manufacturing.12 It also makes speciality ingredients such as probiotics, enzymes, nutritional actives and vitamin analogues.3 Its manufacturing facilities are in Bengaluru.4
It reports 2 segments, CRDMO Services and Speciality Ingredients, and works across small molecules, biologics (medicines made from living cells), peptides, oligonucleotides (short strands of genetic material) and high-potency compounds (active at very small doses).5 Exports made up 85% of revenue from operations in the year to Mar 2026.6 Units I and II meet the standards of regulators including the US FDA, Brazil's ANVISA, Japan's PMDA and Australia's TGA.78 Unit III is run by NeoAnthem Lifesciences, a wholly owned subsidiary, and was commissioned in phases during 2025 and 2026.910
It was incorporated in 2006, and Unit I in Bommasandra was commissioned in 2007.1112 True North, a private equity investor, invested in 2021 and made a full exit in 2026.13 Its founders are Ajay Bhardwaj, Ganesh Sambasivam and K Ravindra Chandrappa; Ajay Bhardwaj is Chairman, Managing Director and Chief Executive Officer.1411 Promoters held 68.58% of the equity at the end of Mar 2026.15
Anthem Biosciences key points
Results
- In the year to Mar 2026, consolidated revenue from operations rose 15.2% to ₹21,243 million, EBITDA (earnings before interest, tax, depreciation and amortisation, including other income) rose 30.8% to ₹9,896 million, the company's EBITDA margin being 43.4%, and profit after tax rose 31.1% to ₹5,918 million.161718
- In the quarter to Jun 2026, consolidated revenue from operations fell 22.6% from a year earlier to ₹4,182 million. EBITDA, including other income of ₹249 million, fell 18.1% to ₹1,755 million, the company's EBITDA margin being 39.6%; profit after tax was ₹1,199 million.192021
- The company's net cash (cash in excess of borrowings) was ₹17,197 million at the end of Jun 2026, against ₹7,848 million a year earlier.2223
- The board recommended a final dividend of ₹2.00 per share for the year to Mar 2026, subject to shareholders' approval.24
Business segments
- Revenue by segment, ₹ million2526CRDMO revenue grew 17.7% and made up 83.4% of total revenue.
Item year to Mar 2026 year to Mar 2025 CRDMO 17,727 15,061 Speciality Ingredients 3,516 3,385 - Revenue by segment, ₹ million27
Item quarter to Jun 2026 quarter to Jun 2025 CRDMO 3,408 4,527 Speciality Ingredients 774 875 - CRDMO Services. Research, development and manufacturing for drug makers: medicinal chemistry, process development, preclinical research and manufacturing to GMP (good manufacturing practice, the quality standard regulators set).28
- Speciality Ingredients. Science-based products for pharmaceutical, nutraceutical and industrial uses. The business is largely focused on India.2930
Plants and capacity
- The company has 3 manufacturing units, and 425 kilolitres (KL) of custom synthesis capacity (making chemical compounds to a customer's order) and 142 KL of fermentation capacity (growing microbes to make a product) across its manufacturing network.3132
- Capacity by unit: custom synthesis / fermentation33
Item Mar 2026 Unit I, Bommasandra 24 KL / 2 KL Unit II, Harohalli 376 KL / 140 KL Unit III (NeoAnthem), Harohalli 25 KL / 40 KL, fermentation yet to be commissioned - In the quarter to Jun 2026, Unit I used about 78% of its custom synthesis capacity, Unit II about 50% of both its custom synthesis and its fermentation capacity, and Unit III 30% to 35%.34
Customers and partners
- Clients by type3536Counting Speciality Ingredients, the company has more than 550 customers.
Item year to Mar 2026 Large pharmaceutical companies 9 Mid-sized pharmaceutical companies 20 Emerging biotech and small pharmaceutical companies 100+ - A partnership with Davos Pharma gives the company access to biotech companies in the US.36
- On its earnings call of 22 Jul 2026, the company said it had added 1 new large pharmaceutical customer, whose agreement was not yet signed.37
Research and development
- In Jun 2026 the company worked on 14 commercial molecules, 10 in late-phase development (Phase III, the last stage of human trials before approval) and more than 100 early-stage programmes.3839
- Customers commercialised 4 molecules in the year to Mar 2026, and commercial molecules brought in 60.8% of revenue that year.40
- R&D services brought in ₹1,732 million, 8.2% of revenue from operations, in the year to Mar 2026. R&D expense was ₹182 million; the company has 2 R&D centres, 13 registered patents and 23 patents filed or pending.4142
Expansion and capital spending
- On its earnings call of 22 Jul 2026, the company said Phase I of Unit IV adds 365 KL of custom synthesis and 100 KL of fermentation capacity for about ₹1,200 crore, and expects it ready by the end of Mar 2028.43
- On its earnings call of 22 Jul 2026, the company said it targets capital spending of about ₹700 crore in the year to Mar 2027.44
What the company expects
- On its earnings call of 22 Jul 2026, the company said it expects growth in the year to Mar 2027 in line with its past record, without giving a percentage, after customers deferred deliveries from the quarter to Jun 2026 to later quarters.454647
- On its earnings call of 22 Jul 2026, the company said orders already in hand (its order book) covered about 60% of what the whole business plans to deliver in the year to Mar 2027.48
- On its earnings call of 22 Jul 2026, the company said it had not started supplying its GLP-1 API (the active ingredient of a class of diabetes and weight-loss drugs), pending approval from CDSCO, India's drug regulator, expected in a quarter or 2.495051
Recent events
- On 2 Jul 2026, ICRA upgraded its long-term rating on the company's bank facilities (its opinion of the ability to repay) to AA (Stable) from AA- (Positive), and reaffirmed the short-term rating of A1+.52
- On 21 Jul 2025, the shares were listed on BSE and NSE after an initial public offering of ₹33,950 million, entirely an offer for sale (existing shareholders selling, so no new money for the company).53
Last updated
All 53 sources, each with its page
- 1. Annual report, 30 Jun 2026, page 38
- 2. Annual report, 30 Jun 2026, page 4
- 3. Annual report, 30 Jun 2026, page 80
- 4. Annual report, 30 Jun 2026, page 81
- 5. Annual report, 30 Jun 2026, page 75
- 6. Annual report, 30 Jun 2026, page 118
- 7. Annual report, 30 Jun 2026, page 81
- 8. Annual report, 30 Jun 2026, page 83
- 9. Annual report, 30 Jun 2026, page 81
- 10. Annual report, 30 Jun 2026, page 39
- 11. Annual report, 30 Jun 2026, page 36
- 12. Annual report, 30 Jun 2026, page 81
- 13. Annual report, 30 Jun 2026, page 5
- 14. Annual report, 30 Jun 2026, page 10
- 15. Annual report, 30 Jun 2026, page 110
- 16. Annual report, 30 Jun 2026, page 83
- 17. Annual report, 30 Jun 2026, page 75
- 18. Annual report, 30 Jun 2026, page 23
- 19. Investor presentation, 21 Jul 2026, page 4
- 20. Investor presentation, 21 Jul 2026, page 7
- 21. Investor presentation, 21 Jul 2026, page 5
- 22. Investor presentation, 21 Jul 2026, page 7
- 23. Investor presentation, 21 Jul 2026, page 5
- 24. Annual report, 30 Jun 2026, page 40
- 25. Annual report, 30 Jun 2026, page 83
- 26. Annual report, 30 Jun 2026, page 83
- 27. Investor presentation, 21 Jul 2026, page 4
- 28. Annual report, 30 Jun 2026, page 77
- 29. Annual report, 30 Jun 2026, page 80
- 30. Earnings call, 22 Jul 2026, page 5
- 31. Annual report, 30 Jun 2026, page 7
- 32. Annual report, 30 Jun 2026, page 81
- 33. Annual report, 30 Jun 2026, page 81
- 34. Earnings call, 22 Jul 2026, page 4
- 35. Annual report, 30 Jun 2026, page 20
- 36. Annual report, 30 Jun 2026, page 21
- 37. Earnings call, 22 Jul 2026, page 5
- 38. Investor presentation, 21 Jul 2026, page 6
- 39. Earnings call, 22 Jul 2026, page 8
- 40. Annual report, 30 Jun 2026, page 20
- 41. Annual report, 30 Jun 2026, page 30
- 42. Annual report, 30 Jun 2026, page 22
- 43. Earnings call, 22 Jul 2026, page 9
- 44. Earnings call, 22 Jul 2026, page 9
- 45. Earnings call, 22 Jul 2026, page 8
- 46. Earnings call, 22 Jul 2026, page 9
- 47. Earnings call, 22 Jul 2026, page 5
- 48. Earnings call, 22 Jul 2026, page 6
- 49. Earnings call, 22 Jul 2026, page 10
- 50. Earnings call, 22 Jul 2026, page 14
- 51. Annual report, 30 Jun 2026, page 20
- 52. Exchange filing, 3 Jul 2026, page 2
- 53. Annual report, 30 Jun 2026, page 38
Results
Consolidated; ₹ crore.Anthem Biosciences quarterly results
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹418 Crdown 31.55%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹120 Crdown 36.79%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 28.7%
Revenue by quarter
Peak revenue ₹611 Cr, quarter to Mar 2026; lowest ₹418 Cr, quarter to Jun 2026
Net profit by quarter, a loss in red
| ₹ crore | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 540 | 550 | 423 | 611 | 418 |
| Net profit | 136 | 173 | 93 | 190 | 120 |
| Net margin | 25.1% | 31.5% | 21.9% | 31.1% | 28.7% |
Consolidated. The 5 quarters from Jun 2025, the first on record. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026
- Revenue
- ₹2,124 Cr
- Net profit
- ₹592 Cr
- Net margin
- 27.9%
| ₹ crore | Mar 2026 |
|---|---|
| Revenue | 2,124 |
| Net profit | 592 |
| Net margin | 27.9% |
Consolidated. Years to March. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- CRDMOCRDMO, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹1,773 Cr83.5%
- Speciality IngredientsSpeciality Ingredients, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹352 Cr16.5%
Valuation
Today, against the company's own history.Anthem Biosciences PE ratio and valuation
Price to book
At or below today's level on 72% of 241 trading days since Nov 2025.
LowestHighest
Its median14.25Industry median2.98
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 85% of 247 trading days over the last year.
LowestHighest
Its median0.00%Industry median0.48%
Mutual fund holdings
155 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 69 of the 93 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 2 more funds filed their first portfolio on record, holding it.All 155 funds holding Anthem Biosciences
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 4
- AddedAdded. Funds that held more shares than at the end of the month before.
- 65
- CutCut. Funds that held fewer shares than at the end of the month before.
- 28
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 56
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 4
| Fund | |||
|---|---|---|---|
 HDFC Flexi Cap FundHDFC Mutual Fund | 74,00,111 | 0.59% | ₹635.4 Cr |
 SBI Midcap FundSBI Mutual Fund | 43,18,200 | 1.59% | ₹370.8 Cr |
 Axis ELSS Tax Saver FundAxis Mutual Fund | 29,22,400 | 0.83% | ₹250.9 Cr |
 Aditya Birla Sun Life Flexi Cap FundAditya Birla Sun Life Mutual Fund | 24,50,000 | 0.75% | ₹210.4 Cr |
| SBI MNC FundSBI Mutual Fund | 22,00,000 | 2.96% | ₹188.9 Cr |
| SBI Healthcare Opportunities FundSBI Mutual Fund | 18,80,000 | 2.75% | ₹161.4 Cr |
| Axis Midcap FundAxis Mutual Fund | 18,52,294 | 0.47% | ₹159.0 Cr |
 UTI Mid Cap FundUTI Mutual Fund | 16,00,000 | 1.15% | ₹137.4 Cr |
 Kotak Multi Asset Allocation FundKotak Mahindra Mutual Fund | 15,79,081 | 0.89% | ₹135.6 Cr |
| HDFC Pharma and Healthcare FundHDFC Mutual Fund | 12,91,629 | 3.17% | ₹110.9 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 29 Oct 2025.Anthem Biosciences insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Others0 purchases, 2 salesNo purchase₹1,338 CrNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.−₹1,338 Cr48 pledge filings of unclear kind
- Promoters and promoter group: no market trade · 2 off-market moves
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Anthem Biosciences competitors and peers
Pharmaceuticals & Biotechnology, 221 listed companies, priced on 29 Oct 2026. The table lists the 8 companies closest to Anthem Biosciences in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 BioconBIOCON | 57,349 | 115.79 | 1.69 | +9.8% | +28.6% | 1.8% | 2.9% | 0.14% |
 Abbott IndiaABBOTINDIA | 55,556 | 34.41 | 11.64 | +6.3% | +11.2% | 35.9% | 39.6% | 2.51% |
 Gland PharmaGLAND | 50,733 | 44.94 | 4.90 | +17.6% | +46.5% | 11.6% | 12.4% | 0.65% |
 IPCA LaboratoriesIPCALAB | 48,869 | 37.31 | 6.06 | +10.6% | +68.2% | 17.4% | 17.6% | 0.31% |
 Ajanta PharmaAJANTPHARM | 43,232 | 38.09 | 9.55 | +20.2% | +22.0% | 27.3% | 27.2% | 1.73% |
 GlaxoSmithKline PharmaceuticalsGLAXO | 42,607 | 39.89 | 18.79 | +5.8% | +12.4% | 50.6% | 56.3% | 2.27% |
 Emcure PharmaceuticalsEMCURE | 35,381 | 34.98 | 7.15 | +18.4% | +35.9% | 21.5% | 25.2% | 0.19% |
 Acutaas ChemicalsACUTAAS | 32,558 | 74.14 | 17.53 | +45.2% | +96.1% | 26.9% | 30.2% | 0.06% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Anthem Biosciences dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹2.00 a share, year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 25 Jun 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹2.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Anthem Biosciences announcements
Oct 2026
28 Oct · Board meeting
Sep 2026
8 Sep · Updates
Jul 2026
22 Jul · Meeting
Anthem Biosciences share price by year
Each calendar year to 2025.Anthem Biosciences share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 651.50 | – | 864.50 | 628.25 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2025 is from its first session, 21 Jul 2025.
Recent sessions
The 9 trading days to 28 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 28 Oct 2026 | 834.00 | 836.55 | 827.05 | 832.15 | 832.56 | 65,491 | 48.3% |
| 27 Oct 2026 | 822.25 | 846.05 | 815.80 | 837.15 | 836.64 | 2,06,744 | 57.6% |
| 26 Oct 2026 | 805.05 | 825.00 | 802.05 | 822.25 | 816.45 | 1,83,681 | 43.7% |
| 23 Oct 2026 | 795.00 | 817.80 | 783.35 | 812.80 | 799.04 | 5,35,896 | 49.5% |
| 22 Oct 2026 | 798.00 | 808.85 | 789.00 | 800.75 | 800.66 | 2,45,422 | 53.8% |
| 21 Oct 2026 | 808.45 | 819.60 | 795.00 | 805.55 | 803.39 | 5,01,179 | 55.0% |
| 19 Oct 2026 | 822.15 | 825.80 | 802.85 | 808.50 | 814.98 | 3,60,867 | 54.7% |
| 16 Oct 2026 | 840.30 | 843.15 | 816.60 | 822.15 | 824.16 | 5,99,949 | 60.2% |
| 15 Oct 2026 | 850.00 | 854.80 | 824.85 | 842.10 | 840.26 | 8,52,912 | 57.2% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- ANTHEM
- BSE code
- 544449
- ISIN
- INE0CZ201020
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.anthembio.com
- CIN
- U24233KA2006PLC039703
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 2006
- Registered office
- No. 49, F1 & F2, Phase 1, Canara Bank Road, Bommasandra Industrial Area, Bommasandra, Bengaluru 560099, Karnataka
- Share registrar
- KFin Technologies Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty 500, BSE 500, Nifty Midcap 150, BSE 250 SmallCap Index, BSE MidCap, Nifty Total Market